# A Study of ARRY-142886 in Patients With Advanced Cancer

> **NCT00085787** · PHASE1 · COMPLETED · sponsor: **Array Biopharma, now a wholly owned subsidiary of Pfizer** · enrollment: 57 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** ARRY-142886, MEK inhibitor; oral

## Key facts

- **NCT ID:** NCT00085787
- **Lead sponsor:** Array Biopharma, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085787, "A Study of ARRY-142886 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00085787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*